Prosjektet ble startet i 2017 og pågår fremdeles. Prosjektet ledes av John Munkhaugen (klinisk del) og Nils Tore Vethe (farmakologisk del). Vi utvikler nye metoder for å måle nivåer av kolesterolsenkende medisiner (statiner) og nedbrytningsprodukter (metabolitter og andre proteiner) i blod og muskel. Metodene benytter vi til å studere legemiddelomsetning og effekter, medikamentetterlevelse og bivirkninger. Den overordnede målsettingen er å utvikle persontilpasset behandling og oppfølging med kolesterolmedisiner slik at pasientene får best mulig effekt, lite bivirkninger og redusert risiko for hjerte-kar sykdom. Prosjektet omfatter metode utviklingsstudier, observasjonsstudier og intervensjonsstudier som du kan lese mer om her:

Metode utviklingsstudier

Observasjonsstudier

Intervensjonsstudier

Prosjektet har 3 PhD stipendiater og en post-doktor forsker.

FORSKNINGSRESULTATER

  1. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy, European Heart Journal Cardiovascular Pharmacotherapy 2024
  2. The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study, Atherosclerosis Plus 2024
  3. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis, 2024
  4. Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms. Clinical Pharmacology and Therapeutics 2023.
  5. Plasma concentration of atorvastatin metabolites correlates with low-densitylipoprotein cholesterol reduction in patients with coronary heart diseasePharmacology Research & Perspectives 2023
  6. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy. European Journal of Preventive Cardiology 2023
  7. Atorvastatin lactone/acid ratios are promising biomarkers for statin dependent muscular side effects in patients with coronary heart diseaseEuropean Journal of Preventive Cardiology 2023
  8. Treatment patterns and adherence to lipid-lowering drugs during 8 years of follow-up after a cardiovascular event. European Heart Journal 2023
  9. Monitoring Simvastatin Adherence in Patients with Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood PlasmaTher Drug Monit, 2022
  10. Clinical and pharmacological characteristics in plasma and mononuclear blood cells in patients with coronary heart disease and low statin toleranceEuropean Journal of Preventive Cardiology (EJPC) 2022 (abstract)
  11.  Tailored clinical management after blinded statin challenge improved long-term lipid control in coronary patients with self-perceived muscle side-effects. European Journal of Preventive Cardiology, 2021
  12. The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease, Atherosclerosis, 2021
  13.  Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovascular Disorders, 2021
  14. .Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial.  European Heart J Cardiovascular Pharmacotherapy, 2020.
  15. Adherence to atorvastatin therapy in coronary prevention evaluated by drug plasma concentrations. Br J Clin Pharmacol. 2019
  16. Statin-associated muscle symptoms in coronary patients: design of a randomized study. Scand Cardiovasc J. 2019
  17. A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. The Drug Monit. 2019